Full-Time

Head of IT

Confirmed live in the last 24 hours

Absci

Absci

51-200 employees

Biotech solutions for protein expression and purification

Biotechnology
Healthcare

Compensation Overview

$220k - $270kAnnually

+ Equity Package

Senior, Expert

Vancouver, WA, USA

Hybrid option 2-3 days/week; consistent on-site presence required.

Category
Cybersecurity
IT Project Management
IT & Security
Required Skills
LLM
Risk Management

You match the following Absci's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • A bachelor’s degree in computer science, electrical engineering, information systems or related technology field (graduate degree a plus)
  • 10+ years of work and management experience in biotech or within laboratory environments, with significant expertise in scaling infrastructure in high-growth organizations, including relevant experience in IT compliance and governance.
  • Strong knowledge of SOX compliance, GxP regulations, 21 CFR Part 11, and data privacy laws (e.g., GDPR, 201 CMR 17.00).
  • Proven expertise in IT security, compliance frameworks, and risk management.
  • Experience with laboratory software and systems such as LIMS (Benchling, Sapio, LAbVantage, STARLIMS, etc.), ELNs, and other laboratory instrument systems
  • Experience with lab instrument hardware/software automation
  • Extensive experience with core ERP and HRIS systems, including integration, maintenance, and workflow optimization.
  • Familiarity with generative AI tools such as OpenAI/ChatrGPT/, LLMs, Github copilot, and the like, as well as privacy and security concerns.
  • Strong organizational and interpersonal skills, project management skills, and ability to communicate cross-functionally across the organization.
Responsibilities
  • Develop and implement an IT roadmap aligned with our strategic growth.
  • Collaborate with AI, Drug Creation, BD, Finance, HR, and Legal/IP teams to drive robust, scalable, and secure systems that support business goals.
  • Provide leadership and mentorship to members of the current IT team.
  • Lead the integration and management of enterprise software, cloud platforms, and network solutions across our IT ecosystem.
  • Anticipate challenges to stay ahead in a dynamic environment.
  • Safeguard our sensitive data by overseeing all security and compliance efforts, including audits and risk management, and ensure alignment with industry regulations.
  • Ensure IT solutions support regulatory requirements.
  • Integrate IT systems that comply with GxP, 21 CFR Part 11, and other regulatory standards.
  • Act as a trusted advisor to senior leadership, translating technical capabilities into business strategy.
  • Communicate IT and business alignment plans to employees, partners, and stakeholders.
  • Implement IT governance frameworks, policies, and risk management strategies, including to maintain SOX and any other relevant regulatory compliance standards.
  • Ensure business continuity, disaster recovery procedures, and data integrity across IT services.
  • Analyze costs, manage the IT budget, and advise on the financial impact of technology decisions.
  • Present IT metrics, KPIs, and project updates to stakeholders.
  • Build and manage relationships with vendors and external partners, negotiate contracts, and ensure the team leverages best-in-class technology to achieve strategic objectives.
Desired Qualifications
  • Direct experience with Netsuite and Coupa

AbSci improves protein expression and biomanufacturing in the biotech industry with its advanced platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system for precise control over protein production. Its standout product, SoluPure, is a chromatography-free purification method that simplifies and speeds up the protein purification process. AbSci sets itself apart from competitors by offering proprietary technologies that enhance drug discovery and manufacturing, aiming to replace traditional methods with more efficient solutions. The company's goal is to introduce efficiencies and cost savings to the biotech industry, transforming the production of biologics.

Company Size

51-200

Company Stage

IPO

Total Funding

$221.7M

Headquarters

Vancouver, Washington

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Absci's partnerships with AMD and Owkin enhance AI-driven drug discovery capabilities.
  • Generative AI collaborations with MSK and Twist Bioscience accelerate novel therapeutic development.
  • Increased adoption of AI and synthetic biology boosts Absci's innovative drug designs.

What critics are saying

  • Growing competition in AI-driven drug discovery may impact Absci's market share.
  • Dependence on partnerships could pose risks if collaborations don't yield results.
  • Rapid tech advancements could render Absci's current technologies obsolete.

What makes Absci unique

  • Absci uses AI and synthetic biology for novel protein-based drug discovery.
  • Their SoluPure method simplifies protein purification, reducing production time and costs.
  • Absci's high-throughput workflow generates active protein products in just three months.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Company Equity

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
GlobeNewswire
Jan 10th, 2025
Absci And Owkin Synergize Leading Techbio Platforms To Advance Generative Ai Drug Discovery

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.” Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids

Aitech365
Jan 9th, 2025
Absci & AMD Announce Collaboration to Boost AI Drug Discovery

Absci Founder & CEO Sean McClain will discuss the strategic partnership at the 43rd Annual J.P.Morgan Healthcare Conference on Wednesday January 15th at 4:30pm PT.

SiliconANGLE
Jan 8th, 2025
AMD invests $20M in Absci's AI drug discovery

AMD has invested $20 million in Absci Corp., an AI-driven drug discovery company. The partnership will see Absci shift some workloads to AMD's Instinct AI processors, enhancing its research capabilities. Absci will use the investment to improve its AI models and collaborate with AMD on developing new hardware and software for healthcare, focusing on drug discovery advancements.

GlobeNewswire
Jan 8th, 2025
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) - Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct(TM) accelerators and ROCm(TM) software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models.

247 Market News
Jan 8th, 2025
"Top Stocks Traders Are Buying Today: SANA, SYTA, CURR, EONR, and ABSI - Hot Picks Driving the Market"

Absci (NASDAQ: ABSI), a leader in AI-driven drug discovery, secured a $20 million strategic investment from Advanced Micro Devices (AMD).